Idelalisib (CAL-101, GS-1101)

For research use only. Not for use in humans.

製品コードS2226

CAS No. 870281-82-6

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.

サイズ

価格(税別)

10mM (1mL in DMSO)	JPY 27800
10mg	JPY 21900
50mg	JPY 80000
200mg	JPY 212800

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297|電子メール：[email protected]|よく尋ねられる質問

文献中Selleckの製品使用例(218)

製品安全説明書

PI3K阻害剤の選択性比較

生物活性

製品説明

ターゲット

p110δ ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)
2.5 nM	89 nM

体外試験

CAL-101 is not sensitive to other PI3K class I subunits including p110α, p110β, and p110γ. CAL-101 specifically blocks FcϵR1 p110δ-mediated CD63 expression with an EC50 of 8 nM in primary basophil. CAL-101 exhibits greater activity in B-cell acute lymphoblastic leukemia (B-ALL) and chronic lymphocytic leukemia (CLL) cells compared with acute myeloid leukemia (AML) and myeloproliferative neoplasm (MPN) cells. CAL-101 produces the reduction in pAktS473, pAktT308, and the downstream target S6 in SU-DHL-5, KARPAS-422 and CCRF-SB cells with EC50 of 0.1 to 1.0 μM. ^[1] CAL-101 induces selective cytotoxicity in CLL cells independent of IgVH mutational status or interphase cytogenetics, primarily through a caspase-dependent mechanism. CAL-101 induces cytotoxicity preferentially to CLL cells compared with normal B cells, without producing cytotoxicity in other hematopoietic cells, compared to LY294002. CAL-101 lacks direct cytotoxic potential to T cells and nature killer (NK) cells. CAL-101 can inhibit production of inflammatory cytokines, such as IL-6, IL-10, TNF-α, and IFN-γ, and activation-induced cytokines, such as CD40L. CAL-101 also antagonizes CD40L-mediated CLL cell survival. ^[2] CAL-101 induces an accumulation of cells in G1 and a decrease in the S-phase population in L1236 and L591 cells, which indicates CAL-101 as a novel strategy for the treatment of hodgkin lymphoma (HL). ^[3]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MEC1	M1XpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2n5eGROW09?	MWLJR\|UxRTJyLkSg{txO	NV:zenIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5PVk{PTJpPkK1PVk6OzV{PD;hQi=>
CLL PBMCs	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUDZfXg3TE2VTx?=	NVntPGFmUUN3ME2yMlkhdk1?	NV7CZZF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NVczPjdpPkK1PVE4OjZ5PD;hQi=>
U266	MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DPb\|QxKM7:TR?=	MVe0PEBp		NGDUV3c4QS53JTDpcohq[mm2aX;uJJJifGV?	NV3GbmhTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN\|k{OzJpPkK1N\|M6OzN{PD;hQi=>
K562	NW\l[ZlwTnWwY4Tpc44hSXO\|YYm=	NX\0bIJEOSEQvF2=	MnLEN{Bp		M4LTd2lvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTBzNEe3OUc,OjVyMUS3O\|U9N2F-
K562	MkTkSpVv[3Srb36gRZN{[Xl?	NVv2ZXN6OSEQvF2=	NVi2bnhVOyCq		MnvpTY5pcWKrdHnvckBw\iCSN{DTOmsheGixc4Doc5J6dGG2aX;u	M1\HTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEG0O\|c2Lz5{NUCxOFc4PTxxYU6=
K562	MUDGeY5kfGmxbjDBd5NigQ>?	NEX3SWkyKM7:TR?=	NGjsWHQ{KGh?		NXT6UJJ{UW6qaXLpeIlwdiCxZjDHV2s{KHCqb4PwbI9zgWyjdHnvci=>	MnTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMUS3O\|UoRjJ3MEG0O\|c2RC:jPh?=
K562	NXTRdWVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYqxJO69VQ>?	M3S5R\|czKGh?		M1;3bWlvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvci=>	M{ThcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEG0O\|c2Lz5{NUCxOFc4PTxxYU6=
Primary AML cell	MonTSpVv[3Srb36gRZN{[Xl?	NUTrc2drOSEQvF2=	NUXFS5p{OyCq		NInyV3lKdmirYnn0bY9vKG:oIFHreEBxcG:\|cHjvdplt[XSrb36=	NYnSSYh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNVQ4PzVpPkK1NFE1Pzd3PD;hQi=>
Primary AML cell	NHHJ[YVHfW6ldHnvckBCe3OjeR?=	M2f2dFEh\|ryP	M3roXlMhcA>?		NUG4bJVkUW6qaXLpeIlwdiCxZjDQO\|BUPkticHjvd5Bpd3K7bHH0bY9v	NGe5VlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCxOFc4PSd-MkWwNVQ4PzV:L3G+
Primary AML cell	NG\LOXZHfW6ldHnvckBCe3OjeR?=	MVmxJO69VQ>?	NH\ZXJM{KGh?		NEj4TWVKdmirYnn0bY9vKG:oIFfTT\|MheGixc4Doc5J6dGG2aX;u	NX\0O3Y6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNVQ4PzVpPkK1NFE1Pzd3PD;hQi=>
Primary AML cell	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLRNXgyKM7:TR?=	MlSxN{Bp		MkjEV5VxeHKnc4Ppc44hd2ZicmLORUB{gW62aHXzbZM>	MlKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMUS3O\|UoRjJ3MEG0O\|c2RC:jPh?=
Microglia	NGfmW4VHfW6ldHnvckBCe3OjeR?=	NGTuSIk2KM7:TR?=	NFO4ToEyOCCq	MUTEUXNQ	MkDYSIVkemWjc3Wgc4YhXE6IYTDz[YNz\XSrb36g[pJwdSCOUGOtd5RqdXWuYYTl[EAheDFzMN80SFkyOEFxREmxNGEhdWmlcn;ncIli	M4GwW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkK1Olg1Lz5{NE[yOVY5PDxxYU6=
Primary CLL cell	MkjrSpVv[3Srb36gRZN{[Xl?	NEH3ZWEyKM7:TR?=	MoTRNVUhdWmw	MUXEUXNQ	MUDCcI9kc3NiQlPSMYlv\HWlZXSgUGNROSC\|ZYLpcoUuPSCjY4TpeoF1cW:w	NVSyXJBQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNFkzOzNpPkK0NFA6OjN\|PD;hQi=>
JEKO-1	NHG4cWhHfW6ldHnvckBCe3OjeR?=	NIHhXJcyKM7:TR?=	MWK3NkBp		M4CzS2lvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbjDpckBK\01vc4TpcZVt[XSnZDDKSWtQNTF?	NXzId5VPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOFE2PDFpPkKzN\|QyPTRzPD;hQi=>
Granta-519	M{fxe2Z2dmO2aX;uJGF{e2G7	M2SxNFEh\|ryP	Mnr3NkBp		MWnJcohq[mm2aX;uJI9nKEGtdDj0N\|A5MSCyaH;zdIhwenmuYYTpc44>	M3f6c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{SxOVQyLz5{M{O0NVU1OTxxYU6=
Granta-519	Mle2SpVv[3Srb36gRZN{[Xl?	MlrhNUDPxE1?	NYTWVVFCOiCq		MkTDTY5pcWKrdHnvckBw\iCDa4Sod\|Q4OylicHjvd5Bpd3K7bHH0bY9v	NH7LS449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O0NVU1OSd-MkOzOFE2PDF:L3G+
JEKO-1	NITpVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzNNVAh\|ryP	NVrBVZZUPzJiaB?=		NFLPbmdKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44he2yrZ3j0cJk>	MnXCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|NEG1OFEoRjJ\|M{SxOVQyRC:jPh?=
JEKO-1	M1nIfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTUNGg2KM7:TR?=	MXq3NkBp		MUXkc4V{KG6xdDDpcoR2[2ViY3XscEBkgWOuZTDhdpJme3Rib4KgZZBweHSxc3nz	NGrDTo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[3OlIzOCd-MkO2O\|YzOjB:L3G+
MAVER-1	M{TqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF6xc4Q2KM7:TR?=	NGrtSIs4OiCq		MoKz[I9meyCwb4SgbY5lfWOnIHPlcIwh[3mlbHWgZZJz\XO2IH;yJIFxd3C2b4Ppdy=>	NXzhfnB6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2O\|YzOjBpPkKzOlc3OjJyPD;hQi=>
MINO	M2ftWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjwVJU2KM7:TR?=	NFLFSIg4OiCq		NXPkWGxO\G:nczDuc5QhcW6mdXPlJINmdGxiY4njcIUh[XK{ZYP0JI9zKGGyb4D0c5Nqew>?	MnzFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4N{[yNlAoRjJ\|Nke2NlIxRC:jPh?=
SP53	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7tO4ZUOC5zIN88US=>	M{H2OFczKGh?		MlHv[I9meyCwb4SgbY5lfWOnIHPlcIwh[3mlbHWgZZJz\XO2IH;yJIFxd3C2b4Ppdy=>	M3vlbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nke2NlIxLz5{M{[3OlIzODxxYU6=
HH	NYLCdoRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXOxNEDPxE1?	Ml\OO\|IhcA>?	NXHJU2JKTE2VTx?=	MYLJcoR2[3Srb36gc4Yh[XCxcITvd4l{KHOuaXfoeIx6	NYGxS\|dJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NFE6PTlpPkKyPFAyQTV7PD;hQi=>
Myla	NUfqcmkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\Pe\|ExKM7:TR?=	M2nOdlczKGh?	MXXEUXNQ	MlT2[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjhyMUm1PUc,OjJ6MEG5OVk9N2F-
SR786	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzJW\|UyOCEQvF2=	Ml;OO\|IhcA>?	NIC2cVVFVVOR	NU\iXmo4\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=>	MlTIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MEG5OVkoRjJ{OECxPVU6RC:jPh?=
HuT78	NIPPTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vqcFExKM7:TR?=	NH7JcVI4OiCq	NEXyTIxFVVOR	MoXX[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?=	Ml;wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MEG5OVkoRjJ{OECxPVU6RC:jPh?=
MJ	MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zTUFExKM7:TR?=	MnTvO\|IhcA>?	MVvEUXNQ	NFzpVYlld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nz	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjhyMUm1PUc,OjJ6MEG5OVk9N2F-
DERL7	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGf5fWgyOCEQvF2=	NX;zXFR1PzJiaB?=	M3exRmROW09?	MnXH[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?=	NH7mXVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiwNVk2QSd-MkK4NFE6PTl:L3G+
L1236	M4jsWGZ2dmO2aX;uJGF{e2G7	M4XRflExKM7:TR?=	MnPJNkBp		MYrJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMEi3O{c,OjJ{MUC4O\|c9N2F-
L428	M1jwd2Z2dmO2aX;uJGF{e2G7	M4q0SFExKM7:TR?=	NIG0TGEzKGh?		MnWzTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:w	MmOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUC4O\|coRjJ{MkGwPFc4RC:jPh?=
L591	NYe1d3VKTnWwY4Tpc44hSXO\|YYm=	NFG0[FgyOCEQvF2=	NVTUVIR1OiCq		NYLoeY5XUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;u	NIjJcVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNFg4Pyd-MkKyNVA5Pzd:L3G+
KMH-2	M1j6T2Z2dmO2aX;uJGF{e2G7	Mkj0NVAh\|ryP	NFTJdmYzKGh?		MnmzTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:w	MkLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUC4O\|coRjJ{MkGwPFc4RC:jPh?=
L1236	M{OxbWZ2dmO2aX;uJGF{e2G7	MUS1JO69VQ>?	MoPXNlQhcA>?		MmP3Roxw[2u\|IIPlZ5JmfGmxbjDv[kB1cGViQ1PMOS=>	NEDhbHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNFg4Pyd-MkKyNVA5Pzd:L3G+
L591	NEn1cVlHfW6ldHnvckBCe3OjeR?=	NFzwXmE2KM7:TR?=	NYL3UYJ[OjRiaB?=		MlX6Roxw[2u\|IIPlZ5JmfGmxbjDv[kB1cGViQ1PMOS=>	NWq2[W9PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVA5PzdpPkKyNlExQDd5PD;hQi=>
L1236	NVnmfnU3SXCxcITvd4l{KEG\|c3H5	NFTkbIk2KM7:TR?=	NF;iUGczPCCq		MnvlTY5lfWO2aX;uJI9nKGGyb4D0c5Nqew>?	NGG4bG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNFg4Pyd-MkKyNVA5Pzd:L3G+
L591	NWTLbW5ISXCxcITvd4l{KEG\|c3H5	NUH1fZRDPSEQvF2=	NEPYVpMzPCCq		MXLJcoR2[3Srb36gc4Yh[XCxcITvd4l{	M{frTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGwPFc4Lz5{MkKxNFg4PzxxYU6=
U-87MG	NGLlTmlHfW6ldHnvckBCe3OjeR?=	MVmxNFAhdk1?	NV3rW5BIOjRiaB?=	MoLISG1UVw>?	NX\m[IxrUW6qaXLpeIlwdiCxZjCgZ4VtdCCvaXfyZZRqd25?	MluzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyN{m2NFkoRjJ{MEe5OlA6RC:jPh?=
SW1783	MUHGeY5kfGmxbjDBd5NigQ>?	MmfTNVAxKG6P	MXiyOEBp	NGLGOohFVVOR	MlWyTY5pcWKrdHnvckBw\iBiY3XscEBucWe{YYTpc44>	Mo\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyN{m2NFkoRjJ{MEe5OlA6RC:jPh?=
U-87MG	NYjrdnBqTnWwY4Tpc44hSXO\|YYm=	MlPGOUDPxE1?	NHzHU3EzPCCq	M2O3[WROW09?	NFi1eoNKdmirYnn0bY9vKG:oIFHreEBxcG:\|cHjvdplt[XSrb36gd5Vje3SjboTpZYxtgQ>?	NGrDUXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC3PVYxQSd-MkKwO\|k3ODl:L3G+
SW1783	M{\WemZ2dmO2aX;uJGF{e2G7	NFLTS2w2KM7:TR?=	M3K0[FI1KGh?	NHXRS2NFVVOR	MVvJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25ic4Xid5RidnSrYXzsfS=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB5OU[wPUc,OjJyN{m2NFk9N2F-
U-373MG	MkTpSpVv[3Srb36gRZN{[Xl?	NGHM[3Q2KM7:TR?=	NWLWNm5jOjRiaB?=	M2OxWGROW09?	M{jr[2lvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbjDzeYJ{fGGwdHnhcIx6	M3fhSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEe5OlA6Lz5{MkC3PVYxQTxxYU6=
SK-MG3	MXHGeY5kfGmxbjDBd5NigQ>?	MYC1JO69VQ>?	M2fwOFI1KGh?	MVXEUXNQ	MVTJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25ic4Xid5RidnSrYXzsfS=>	NUjXTHhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwO\|k3ODlpPkKyNFc6PjB7PD;hQi=>
SU-DHL-5	MmHMSpVv[3Srb36gRZN{[Xl?	MXWxJO69VQ>?	MmSwNlQhcA>?	MkLkSG1UVw>?	NUTrNXVUUW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?=	NH65TY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEm1PVYxPid-MkC5OVk3ODZ:L3G+
WSU-NHL	MUfGeY5kfGmxbjDBd5NigQ>?	NH3ZOlIyKM7:TR?=	NUXHcpIxOjRiaB?=	NEfvZ4pFVVOR	M3nrTGlv\HWldHnvckBw\iCjcH;weI9{cXN?	MlHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7NUm2NFYoRjJyOUW5OlA3RC:jPh?=
CCRF-SB	MXXGeY5kfGmxbjDBd5NigQ>?	MWCxJO69VQ>?	NFThVI8zPCCq	MlvySG1UVw>?	MlfuTY5lfWO2aX;uJI9nKGGyb4D0c5Nqew>?	M2rCTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOUW5OlA3Lz5{MEm1PVYxPjxxYU6=
INA-6	MUTGeY5kfGmxbjDBd5NigQ>?	NE[4b5U2KM7:TR?=	M4riT\|YhcA>?		NWjIb2N{UW6qaXLpeIlwdiCxZjDQTVNMN0GtdDDhcoQhTVKNIIDheIh4[Xl?	M1O1RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUC1NVU5Lz5{MEWwOVE2QDxxYU6=
LB	M2PKNmZ2dmO2aX;uJGF{e2G7	NXizRllsPSEQvF2=	NUTvNpJiPiCq		NUXJdJJRUW6qaXLpeIlwdiCxZjDQTVRMN0GtdDDhcoQhTVKNIIDheIh4[Xl?	NFrtNG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEWwOVE2QCd-MkC1NFUyPTh:L3G+
B-cells	NELwNo9HfW6ldHnvckBie3OjeR?=				M4jyVWlvcGmkaYTpc44hd2ZiUFmzT4RmdHSjIHnuJGIu[2WubIOgZpkheHKxbHnm[ZJifGmxbjDhd5NigSxiSVO1NEA:KDBwMEC2NUDPxE1w	M4e2R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUK0Olg5Lz5{MkmyOFY5QDxxYU6=
MOLM14	M2PBe2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		M4iyTlMh\GG7cx?=		NE\NXGdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yPCClZXzsd{Bi\nSncjCzJIRigXNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFMvPiEQvF2u	MknRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5N{SxNlcoRjJ5N{e0NVI4RC:jPh?=
MV4-11	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MmnrN{Bl[Xm\|		MYHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2YND2xNUBk\WyuczDh[pRmeiB\|IHThfZMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IE[uN{DPxE1w	M1XqT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVI4Lz5{N{e3OFEzPzxxYU6=
Jurkat	Moe0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NF7G[XU{KGSjeYO=		NYDuO5U1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDKeZJs[XRiY3XscJMh[W[2ZYKgN{Bl[Xm\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEmFNUCgQUA4NjlizszNMi=>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5NEGyO{c,Ojd5N{SxNlc9N2F-
Loucy	NEjaW3pCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MoLyN{Bl[Xm\|		NHHJNZNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzveYN6KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBKSzVyIE2gPE41KM7:TT6=	M133S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVI4Lz5{N{e3OFEzPzxxYU6=
MOLT4	M1v5ZmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MYCzJIRigXN?		MmTBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPT1zUOEBk\WyuczDh[pRmeiB\|IHThfZMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IEGwMlYh\|ryPLh?=	NX:1bIhtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O\|QyOjdpPkK3O\|c1OTJ5PD;hQi=>
insect cells	M2nxVmZ2dmO2aX;uJIF{e2G7				NVLIUoh5UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtKGynbnf0bEBJcXNvdHHn[4VlKFCLM1vnZY1u[SCneIDy[ZN{\WRiaX6gbY5{\WO2IHPlcIx{NCCLQ{WwJF0hOC5yOEmg{txONg>?	NVfnUYlvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4OFY1PTFpPkK3PFQ3PDVzPD;hQi=>
SUDHL6	MYLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MVG3NkBpenN?		Ml;URY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVVVTIUFYh[2WubIOgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR\|UxKD1iMD6xNVc3KM7:TT6=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzh2NkS1NUc,Ojd6NE[0OVE9N2F-
insect cells	MoPaSpVv[3Srb36gZZN{[Xl?				NXnRSHlWUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtKGynbnf0bEBJcXNvdHHn[4VlKFCLM1vi[ZRiKGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMtKEmFNUCgQUAxNjV4NTFOwG0v	MnzkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6NE[0OVEoRjJ5OES2OFUyRC:jPh?=
SU-DHL4	NHXuOlRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NIW3[WY4OiCqcoO=		Mm\KRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVVT3ETGw1KGOnbHzzJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IEGuOkDPxE1w	NHO0Xlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{i0OlQ2OSd-Mke4OFY1PTF:L3G+
Pfeiffer	MXLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NXnqXVZLPzJiaILz		NYfZdI4{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQ[oVq\m[ncjDj[YxteyCvZXHzeZJm\CCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUA3NjhizszNMi=>	M{n1U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OES2OFUyLz5{N{i0OlQ2OTxxYU6=
KARPAS422	MoHWRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MXe3NkBpenN?		NXTRfVltSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRXJRSVN2MkKgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hQC5zIN88UU4>	Mke0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6NE[0OVEoRjJ5OES2OFUyRC:jPh?=
Sf21	Mmf6SpVv[3Srb36gZZN{[Xl?		MojjN\|AhdWmwcx?=		MWXJcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiSHnzOk11[WepZXSgdoVkd22kaX7hcpQh\nWubD3s[Y5ofGhiaIXtZY4hWEl\|SzDwNVEx[mW2YT;1cpRi\2enZDDy[YNwdWKrbnHueEBnfWyuIHzlcod1cCCqdX3hckBxQDWjbIDoZUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgV4YzOSCrboPlZ5Qh[2WubIOgeZNqdmdiUFnQNk9CXFBiYYOgd5Vje3S{YYTlJIFnfGW{IEOwJI1qdnNiYomgWHIuTlKHVDDhd5NigSxiSVO1NEA:KDNwNzFOwG0v	M4XLWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUC2PVkyLz5{OEGwOlk6OTxxYU6=
Sf21	NUPxXYJtTnWwY4Tpc44h[XO\|YYm=		M1jk[lMxKG2rboO=		NVjVbWZvUW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGhqezZvdHHn[4VlKHKnY3;tZolv[W62IH\1cIwudGWwZ4ToJIh2dWGwIGDJN2sheDFzMHLleIEwfW62YXfn[YQhemWlb33ibY5idnRiZoXscEBt\W6pdHigbJVu[W5icEi1ZYxxcGFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoMkGgbY5{\WO2IHPlcIx{KHW\|aX7nJHBKWDJxQWTQJIF{KHO3YoP0doF1\SCjZoTldkA{OCCvaX7zJIJ6KFSULV\SSXQh[XO\|YYmsJGlEPTBiPTCzMlch\|ryPLh?=	NHTvfZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEGwOlk6OSd-MkixNFY6QTF:L3G+
RPMI8266	M3jsOmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NUDzc5k6PzJiaILz		NF\1Z49CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGLQUWk5OjZ4IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjByNUS5JO69VS5?	M3nUXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{K1OlAyLz5{OEOyOVYxOTxxYU6=
Raji	NFfrfHRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M4GwfVczKGi{cx?=		NF3YXGJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGLhbokh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFA6QTVizszNMi=>	M1nH[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{K1OlAyLz5{OEOyOVYxOTxxYU6=
KARPAS422	NYrI[HpyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NGflT4JIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBMSVKSQWO0NlIh[2WubIOgZpkhS0ONODDhd5NigSxiR1m1NEA:KDBwNkig{txONg>?	MoewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6M{W4NFUoRjJ6OEO1PFA2RC:jPh?=
Pfeiffer	NX;LZ5JRT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NYnPU2MxT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWG[naX\m[ZIh[2WubIOgZpkhS0ONODDhd5NigSxiR1m1NEA:KDBwN{Sg{txONg>?	NFLDT3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEizOVgxPSd-Mki4N\|U5ODV:L3G+
Saos-2	NGKyZ5ZyUFSVIHHzd4F6				NV;VdoxZeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	MV\xTHRUKGG\|c3H5				NWf2RYNleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM>	Ml7EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	NYHwUYp7eUiWUzDhd5NigQ>?				NVPD[FJOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	NUPtOHEyeUiWUzDhd5NigQ>?				Mlv6dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	MoDkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	MmThdWhVWyCjc4PhfS=>				M3KyepFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	M3rBXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	MVHxTHRUKGG\|c3H5				NU\rfnc6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO=	M{XjVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	MX;xTHRUKGG\|c3H5				NVPNZZljeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	NIDlfVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	MUfxTHRUKGG\|c3H5				MWTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	NXjDNWVweUiWUzDhd5NigQ>?				MlT1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SUDHL6	M4jIe2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYnLZndjPzJiaILz		M2C1W2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2XETGw3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDR2s5KGG\|c3H5MEBKSzVyIE2gNE43PSEQvF2u	M1fRWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUO0PVM3Lz5{OUWzOFk{PjxxYU6=
RPMI8226	NWLrO2I5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mk\1O\|IhcHK\|		M1P4WmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmDNTVgzOjZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFUvPDlizszNMi=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV\|NEmzOkc,Ojl3M{S5N\|Y9N2F-
Raji	MmjJRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M2e3dVczKGi{cx?=		MlHqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCUYXrpJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB7Lkm1JO69VS5?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV\|NEmzOkc,Ojl3M{S5N\|Y9N2F-
SU-DHL6	Mn33S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MmDqS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV3UuTEiONjDj[YxteyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4xPDJizszNMi=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZyMUm5NUc,Ojl4MEG5PVE9N2F-
MOLM13	MnrjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Ml3BO\|IhcHK\|		M1f1O2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1QVE1zMzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDseY1qdmW\|Y3XueEBie3OjeTygS2k2OCB;IEGuO{DPxE1w	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB3M{eyNUc,OzByNUO3NlE9N2F-
MOLM14	M3W1[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MnHLO\|IhcHK\|		MkPkS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUW9NVTF2IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHz1cYlv\XOlZX70JIF{e2G7LDDHTVUxKD1iNj60JO69VS5?	MkK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNUO3NlEoRjNyMEWzO\|IyRC:jPh?=
MOLM14	M4TGdGFvfGm2dX3vdkBie3OjeR?=	MmXnNVAxKG2pL3vn	NEGz[3AyPCCmYYnz		MkDLRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE1KGOnbHzzJJhmdm:pcnHmeIVlKGmwIH71M452KG2xdYPlJIF{e2W\|c3XkJIF{KHS3bX;yJIdzd3e2aDDpcohq[mm2aX;uJIF1KDFyMDDt[{9s\yxicH:gZYRucW6rc4TldoVlKGSjaXz5JJZq[SCpYY\h[4Uh\G:\|ZXSg[o9zKDF2IHThfZMh[W6mIH3lZZN2emWmIHThbYx6KGS3cnnu[{Bkd22yb4Xu[EBld3OrbnegdoVt[XSrdnWgeI8h[2:wdILvcC=>	NI\FZ5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC1N\|czOSd-M{CwOVM4OjF:L3G+
MOLM14	MVTBcpRqfHWvb4KgZZN{[Xl?	MlTrNVAxKG2pL3vn	M4\pU\|E1KGSjeYO=		M2rTWGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yPCClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDueU9vfSCvb4Xz[UBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gZZBweHSxc3nzJIF1KDFyMDDt[{9s\yxicH:gZYRucW6rc4TldoVlKGSjaXz5JJZq[SCpYY\h[4Uh\G:\|ZXSg[o9zKDF2IHThfZMh[W6mIH3lZZN2emWmIHThbYx6KGS3cnnu[{Bkd22yb4Xu[EBld3OrbnegZpkhXFWQRVygZoF{\WRiYYPzZZk>	NU\4XIJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOVM4OjFpPkOwNFU{PzJzPD;hQi=>
MOLM14	MnyyRY51cXS3bX;yJIF{e2G7	MWixNFAhdWdxa3e=	M3KxbVE1KGSjeYO=		NWjBXXhESW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUW9NVTF2IHPlcIx{KHinbn;ndoFnfGWmIHnuJI52N263IH3veZNmKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhfHWvb4KgdJJwdGmoZYLheIlwdiBzMECgcYcwc2duIIDvJIFldWmwaYP0[ZJm\CCmYXnsfUB3cWFiZ3H2ZYdmKGSxc3XkJIZweiBzNDDkZZl{KGGwZDDt[YF{fXKnZDDkZYltgSCmdYLpcoch[2:vcH;1coQh\G:\|aX7nJIJ6KEurLU[3JIxi[mWubHnu[{Bj[XOnZDDpcY12dm:q	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB3M{eyNUc,OzByNUO3NlE9N2F-

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	Akt(T308) / PDK1(S241) / GSK-3β(S9); PubMed: 27342398 Clin Cancer Res JeKo-1, Mino, and Granta 519 cells or cells from four different MCL patients were serum-starved for 1h and then treated with DMSO, or with 0.5, 1, or 3μM for 1h; the cells were then co-cultured with IgM (10ng/μL) for 15min before harvesting. Cell extracts were prepared, and 30μg (cell lines) or 50μg (primary cells) protein was loaded for immunoblot analyses. The effects of idelalisib on Akt (Thr308) and total Akt, PDK1 (Ser241) and total PDK1, GS3K-3β (Ser9) and total GSK-3β protein expression levels were detected in (A) JeKo-1, Mino and Granta 519 cells. p-FoxO3a / FoxO3a; PubMed: 30224718 Cell Death Dis HepG2 cells were treated with 5 μmol/L idelalisib for 24 h. Indicated protein expression was analyzed by western blotting and p-FoxO3a normalized to FoxO3a, p-AKT normalized to AKT. The data represent the mean ± SD of three independent experiments. P < 0.01 (one-way ANOVA with Tukey’s post hoc test). Mcl-1 / Bcl-2 / Bid / Bcl-xl / Noxa / Bak / Bax ; PubMed: 30224718 Cell Death Dis HepG2 cells were treated with 5 μmol/L idelalisib at indicated time points. The expression of indicated Bcl-2 family members was analyzed by western blotting and normalized to β-actin. The data represent the mean ± SD of three independent experiments. P < 0.01 (one-way ANOVA with Tukey’s post hoc test). Cleaved caspase 3 / Cleaved caspase 9; PubMed: 28008149 Oncotarget HepG2 cells were treated with 5μmol/L idelalisib at indicated time point. Cleaved-caspase 3 and 9 were analyzed by western blotting. p-AKT / AKT; PubMed: 28008149 Oncotarget HCT116 cells were treated with 10 μmol/L idelalisib at indicated time point. Total AKT and p-AKT expression was analyzed Western blotting. p-p65; PubMed: 28008149 Oncotarget HCT116 cells were treated with 10 μmol/L idelalisib at indicated time point. p-p65 (S536) and p65 expression was analyzed by Western blotting. Bim / Bcl-xl / Bid / Mcl-1; PubMed: 28008149 Oncotarget HCT116 cells treated with 10 μmol/L idelalisib at indicated time point. The expression of indicated Bcl-2 family members was analyzed by Western blotting. PUMA / p53 ; PubMed: 28008149 Oncotarget Parental and p53-KD HCT116 cells were treated with 10 μmol/L idelalisib for 24 hours. PUMA expression was analyzed by Western blotting.	27342398 30224718 28008149
Growth inhibition assay	Cell viability; PubMed: 30224718 Cell Death Dis The indicated cell lines were treated with increasing concentrations of idelalisib for 72 h. Cell viability was determined by MTS assay. Cell viability; PubMed: 28008149 Oncotarget Indicated cell lines were treated with different concentrations of idelalisib for 72 hours. Cell proliferation was determined by MTS assay. Results were expressed as means ± SD of three independent experiments.	30224718 28008149

お薦めの試験操作（参考用のみ）

キナーゼ試験：^[2]	- 合併 PI3K assay: PI3K assay is preformed on whole-cell lysates from CLL or normal B cells. A PI3K ELISA assay is performed. Briefly, whole-cell extracts are added to a mixture of PI(4,5)P2 substrate and reaction buffer containing adenosine triphosphate (ATP) and allowed to incubate at room temperature. The reaction is stopped by adding PI(3,4,5)P3 detector mixed with EDTA (ethylenediaminetetraacetic acid) and allowed to incubate at room temperature for 1 hour. After this time, the mixture is transferred from each well to a PI3K ELISA plate and allowed to incubate 1 hour. Plates are washed and then incubated with secondary detector for 30 minutes. Plates are washed again, and 3,3′,5,5′-tetramethylbenzidine solution is added for 5 minutes at which time H2SO4 is added to stop all reactions. Plates are read at 450 nm on a Labsystems 96-well plate reader.
細胞試験： ^[2]	- 合併細胞株： CLL B cells or healthy volunteer T cells or NK cells 濃度： 0.01-100 μM 反応時間： 48 hours 実験の流れ： MTT assays are performed to determine cytotoxicity. 1 × 10⁵ cells are incubated with CAL-101. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. DMSO is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed. At least 104 cells are counted for each sample. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis included the addition of 100 μM Z-VAD. Experiments examining survival signals include the addition of 1 μg/mL CD40L, 800 U/mL IL-4, 50 ng/mL BAFF, 20 ng/mL TNF-α, or coculturing on fibronectin or stromal (HS-5 cell line) coated plates. Stromal coculture is done by plating a 75-cm² flask (80%-100% confluent) per 6-well plate 24 hours before the addition of CLL cells. (参考用のみ)

キナーゼ試験：^[2]

- 合併

PI3K assay:

PI3K assay is preformed on whole-cell lysates from CLL or normal B cells. A PI3K ELISA assay is performed. Briefly, whole-cell extracts are added to a mixture of PI(4,5)P2 substrate and reaction buffer containing adenosine triphosphate (ATP) and allowed to incubate at room temperature. The reaction is stopped by adding PI(3,4,5)P3 detector mixed with EDTA (ethylenediaminetetraacetic acid) and allowed to incubate at room temperature for 1 hour. After this time, the mixture is transferred from each well to a PI3K ELISA plate and allowed to incubate 1 hour. Plates are washed and then incubated with secondary detector for 30 minutes. Plates are washed again, and 3,3′,5,5′-tetramethylbenzidine solution is added for 5 minutes at which time H2SO4 is added to stop all reactions. Plates are read at 450 nm on a Labsystems 96-well plate reader.

細胞試験： ^[2]

- 合併

細胞株： CLL B cells or healthy volunteer T cells or NK cells
濃度： 0.01-100 μM
反応時間： 48 hours
実験の流れ： MTT assays are performed to determine cytotoxicity. 1 × 10⁵ cells are incubated with CAL-101. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. DMSO is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed. At least 104 cells are counted for each sample. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis included the addition of 100 μM Z-VAD. Experiments examining survival signals include the addition of 1 μg/mL CD40L, 800 U/mL IL-4, 50 ng/mL BAFF, 20 ng/mL TNF-α, or coculturing on fibronectin or stromal (HS-5 cell line) coated plates. Stromal coculture is done by plating a 75-cm² flask (80%-100% confluent) per 6-well plate 24 hours before the addition of CLL cells.
(参考用のみ)

参考

溶解度 (25°C)

体外	DMSO	83 mg/mL (199.79 mM) warming
	Ethanol	23 mg/mL (55.36 mM)
	Water	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 2% DMSO+20%PEG 300+ddH2O 混合させたのち直ちに使用することを推奨します。	5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Idelalisib (CAL-101, GS-1101) SDFをダウンロードする

分子量	415.42
化学式	C₂₂H₁₈FN₇O
CAS No.	870281-82-6
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	N/A
Smiles	CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03582098	Completed	Drug: Idelalisib\|Drug: Rituximab	Chronic Lymphocytic Leukaemia	Gilead Sciences	September 12 2018	--
NCT03151057	Active not recruiting	Drug: Idelalisib 100 MG\|Drug: Placebo Oral Tablet	B Cells-Tumors\|B Cell Chronic Lymphocytic Leukemia\|Follicular Lymphoma\|Mantle Cell Lymphoma\|Large B-Cell Diffuse Lymphoma of Bone (Diagnosis)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Gilead Sciences	July 31 2018	Phase 1
NCT03568929	Active not recruiting	Drug: Idelalisib	Follicular Non-Hodgkin''s Lymphoma Refractory	Gilead Sciences	May 25 2018	--

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須
*大学・企業名:
*名前:
*電子メール:
*電話番号:
*内容:

よくある質問（FAQ）

質問1：
What is the recommended dose of CAL-101 and the route of administration for mouse studies?
回答：
According to the following paper, S2226 can be used by I.V. administration at the concentration of 40 mg/kg. https://www.ncbi.nlm.nih.gov/pubmed/24625684

PI3Kシグナル伝達経路

PI3K Inhibitors with Unique Features

Pan PI3K Inhibitor

LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
PI3K Inhibitor in Clinical Trial

Hexestrol : Phase II for Advanced Breast Cancer.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

相関PI3K製品

Taselisib (GDC 0032)

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147)

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Wortmannin (KY 12420)

Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Dactolisib (BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.

研究分野別

製品類型

Idelalisib (CAL-101, GS-1101)

文献中Selleckの製品使用例(218)

製品安全説明書

PI3K阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Idelalisib (CAL-101, GS-1101) SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技術サポート

よくある質問（FAQ）

PI3Kシグナル伝達経路

PI3K Inhibitors with Unique Features

相関PI3K製品